Strategy includes a team of eight and provides a platform of due diligence products to support investment decisions for the medical device industry for venture capitalists, emerging companies seeking funding and for companies seeking to prioritize the indication for use with the highest probability of successful commercialization. Their clients consistently tell them that it is as if “Strategy Inc. can see the future.” This strategic insight emerges from solid, in-the-trenches analysis by a team of dedicated lifescience professionals who have been working together for ten years, each with a minimum of 10 years of domain experience. A summary of Strategy Inc’s product portfolio can be found in the following:

Market Analysis: A Strategy Inc. market analysis defines the potential for commercial success for the identified target markets. The analysis includes identification of current and emerging treatment modalities, market drivers and projected barriers to market adoption, target customer profile, and market penetration forecast.

Valuation: A Strategy Inc. valuation supports negotiation from a position of strength with a defensible bottom line backed by in-depth quantitative financial techniques and market analysis based on current industry trends. A Strategy Inc. valuation can also drive refinement of corporate strategy in advance of capital formation and acquisition activities.

Clinical Assessment: A Strategy Inc. clinical assessment includes interview comments from 15-30 carefully selected physicians around the globe based on their published literature, presentations and recommendations. Physicians are mostly key opinion leaders but include the more routine physicians for reality-based decision making. Asking the tough questions ensures our clients can forecast adoption.

Competitive Analysis: A Strategy Inc. competitive analysis incorporates the full competitive landscape that includes future technologies that may be barely “on-the-horizon”. Such insight facilitates selection of the optimal “space” for a technology and supports product positioning and feature set identification that drive adoption.

Risk Analysis: A Strategy Inc. risk analysis outlines the most direct path to successful commercialization, mitigating the known and potential risk of product development. Comprehension of specific strengths, weaknesses, opportunities and threats for technology, clinical, market acceptance, competition, regulatory and financial provide the needed blue print for success